Post by Tony Crispino on Jan 23, 2014 12:35:49 GMT -8
The annual American Society of Clinical Oncology GU Conference starts next week and it's going to be newsworthy for prostate cancer. I am hearing the following:
1> The ECOG-ACRIN Co-op will be releasing the technical data on the CHAARTED trial that was announced in November. Results are in and it is expected to be a game changer for men diagnosed with extensive mets. As a refresher, CHAARTED was a trial that teated earlier use of docetaxel based chemotherapy in men with confirm mets. Previously the standard of care was HT with an LHRH agonist + casodex alone until it no longer was effective followed by 2nd line HT drugs before using docetaxel + predisone. But CHAARTED shows us that early chemo is better in men with extensive mets providing significant survival benefit. There was no significant benefit for men with lesser mets. However it is felt that more time may in fact confirm a benefit in these patients. It will be a very anticipated release of information and probably the one of two major discussions at this years summit.
2> Low Risk and Very Low Risk cancers will be evaluated and it is possible that ASCO will make a major announcement on the standard of care for these patients. We have already heard from a few consortiums on recommendations but we have not heard from ASCO. I expect to see standards for active surveillance and a more slow roll to therapy for these patients. What I don't expect to see is a consensus. What will likely come out of this will be newsworthy and impactful. I know quite a few physicians, including our SRB members that will be involved in these discussions. There is no consensus among the ones I know.
ASCO GU Symposium
Tony
1> The ECOG-ACRIN Co-op will be releasing the technical data on the CHAARTED trial that was announced in November. Results are in and it is expected to be a game changer for men diagnosed with extensive mets. As a refresher, CHAARTED was a trial that teated earlier use of docetaxel based chemotherapy in men with confirm mets. Previously the standard of care was HT with an LHRH agonist + casodex alone until it no longer was effective followed by 2nd line HT drugs before using docetaxel + predisone. But CHAARTED shows us that early chemo is better in men with extensive mets providing significant survival benefit. There was no significant benefit for men with lesser mets. However it is felt that more time may in fact confirm a benefit in these patients. It will be a very anticipated release of information and probably the one of two major discussions at this years summit.
2> Low Risk and Very Low Risk cancers will be evaluated and it is possible that ASCO will make a major announcement on the standard of care for these patients. We have already heard from a few consortiums on recommendations but we have not heard from ASCO. I expect to see standards for active surveillance and a more slow roll to therapy for these patients. What I don't expect to see is a consensus. What will likely come out of this will be newsworthy and impactful. I know quite a few physicians, including our SRB members that will be involved in these discussions. There is no consensus among the ones I know.
ASCO GU Symposium
Tony
